Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices

Autor: Ruoding Tan, Lourenia Cassoli, Ying Yan, Vincent Shen, Bann-mo Day, Edith P. Mitchell

Publikováno v: Frontiers in Public Health, Vol 10 (2022)

ObjectiveReal-world data characterizing differences between African American (AA) and White women with metastatic triple-negative breast cancer (mTNBC) are limited. Using 9 years of data collected from community practices throughout the United States

Externí odkaz: https://doaj.org/article/547aff7185b94ef7a778bdd663860e05

Abstract PS7-53: Assessing racial differences in patients with metastatic triple-negative breast cancer: Real-world evidence from US community oncology practices

Autor: Edith P. Mitchell, Vincent Shen, Amie Tan, Luciana Preger, Bann-mo Day

Publikováno v: Cancer Research. 81:PS7-53

Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive tumor phenotype with a poor prognosis and few treatment options. The prevalence of mTNBC is disproportionately higher among African American (AA) women, compared with white

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::acff929cc309b1045764a99a862a485a
https://doi.org/10.1158/1538-7445.sabcs20-ps7-53

Abstract P3-10-11: Entrectinib in NTRK fusion-positive breast cancer: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

Autor: Saiama N. Waqar, Collin M. Blakely, Janice Lu, Minal A. Barve, B. Simmons, Christophe Le Tourneau, Xinhui Huang, Bann-mo Day

Publikováno v: Cancer Research. 80:P3-10

Background Fusions involving the neurotrophic tropomyosin receptor kinase (NTRK) gene family NTRK1, NTRK2, and NTRK3 lead to the expression of chimeric rearrangements in the TRK tyrosine kinase proteins (TRKA, TRKB, and TRKC, respectively) with const

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eee42885ca44e8d58ed883f3fd76451b
https://doi.org/10.1158/1538-7445.sabcs19-p3-10-11

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Autor: Chia-Chi Lin, Anna F. Farago, Timothy R. Wilson, Bann Mo Day, Chao Hua Chiu, Filippo de Braud, David Chen, Yu Chung Li, Rafal Dziadziuszko, Fabrice Barlesi, Byoung Chul Cho, Matthew G Krebs, Manish R. Patel, Stephen V. Liu, Salvatore Siena, Christos S. Karapetis, Alexander Drilon, Robert C. Doebele, Myung-Ju Ahn

Publikováno v: Dziadziuszko, R, Krebs, M G, de Braud, F, Siena, S, Drilon, A, Doebele, R C, Patel, M R, Chul Cho, B, Liu, S V, Ahn, M J, Chiu, C H, Farago, A F, Lin, C C, Karapetis, C S, Li, Y C, Day, B M, Chen, D, Wilson, T R & Barlesi, F 2021, ' Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer ', Journal of Clinical Oncology, vol. 39, no. 11, pp. 1253-1263 . https://doi.org/10.1200/JCO.20.03025

PURPOSE Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 ( ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a05220555a26418c94033b7ba1f3ff5
https://doi.org/10.1200/JCO.20.03025

Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic

Autor: Chau T. Dang, Sara M. Tolaney, Fauzia Riaz, Antoinette R. Tan, Katherine H. R. Tkaczuk, Anthony Francis Yu, Jennifer Liu, Anita M. Fung, Anna Yang, Bann-mo Day, Hope S. Rugo

Publikováno v: Journal of Clinical Oncology. 40:1515-1515

1515 Background: Standard of care for HER2+ early/first-line metastatic BC (EBC/MBC) is P + H and concurrent chemotherapy (CT); PH FDC SC offers faster, more convenient admin vs intravenous (IV) P + H. COVID-19 has caused unprecedented strain on heal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::90e19d0f2bdb27e40911f12ddeedf894
https://doi.org/10.1200/jco.2022.40.16_suppl.1515